{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:14:42Z","timestamp":1764080082563,"version":"3.40.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Natural Science Foundation","doi-asserted-by":"crossref","award":["ZR2021LSW023","ZR2022MH111","ZR2021QH356","ZR2022MH103"],"award-info":[{"award-number":["ZR2021LSW023","ZR2022MH111","ZR2021QH356","ZR2022MH103"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018627","name":"Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China","doi-asserted-by":"publisher","award":["202009031334"],"award-info":[{"award-number":["202009031334"]}],"id":[{"id":"10.13039\/501100018627","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03654-7","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T10:02:22Z","timestamp":1723111342000},"page":"1026-1038","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical efficacy and safety of immune checkpoint inhibitors plus anlotinib as secondline or subsequent therapy in extensive stage small cell lung cancer: a retrospective study"],"prefix":"10.1007","volume":"27","author":[{"given":"Yanan","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanjing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajuan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6988-878X","authenticated-orcid":false,"given":"Jiandong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"3654_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7:3. https:\/\/doi.org\/10.1038\/s41572-020-00235-0.","journal-title":"Nat Rev Dis Primers"},{"key":"3654_CR2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/jco.21.01881","volume":"40","author":"J Zugazagoitia","year":"2022","unstructured":"Zugazagoitia J, Paz-Ares L. Extensive-stage small-cell lung cancer: first-line and second-line treatment options. J Clin Oncol. 2022;40:671\u201380. https:\/\/doi.org\/10.1200\/jco.21.01881.","journal-title":"J Clin Oncol"},{"key":"3654_CR3","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1200\/jco.2009.23.1548","volume":"27","author":"MA Socinski","year":"2009","unstructured":"Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009;27:4787\u201392. https:\/\/doi.org\/10.1200\/jco.2009.23.1548.","journal-title":"J Clin Oncol"},{"key":"3654_CR4","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1809064.","journal-title":"N Engl J Med"},{"key":"3654_CR5","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/s0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929\u201339. https:\/\/doi.org\/10.1016\/s0140-6736(19)32222-6.","journal-title":"Lancet"},{"key":"3654_CR6","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1200\/jco.2013.51.4109","volume":"32","author":"JW Allen","year":"2014","unstructured":"Allen JW, Moon J, Redman M, Gadgeel SM, Kelly K, Mack PC, et al. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol. 2014;32:2463\u201370. https:\/\/doi.org\/10.1200\/jco.2013.51.4109.","journal-title":"J Clin Oncol"},{"key":"3654_CR7","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1200\/jco.2013.54.5392","volume":"32","author":"J Von Pawel","year":"2014","unstructured":"Von Pawel J, Jotte R, Spigel DR, O\u2019Brien ME, Socinski MA, Mezger J, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32:4012\u20139. https:\/\/doi.org\/10.1200\/jco.2013.54.5392.","journal-title":"J Clin Oncol"},{"key":"3654_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","volume":"32","author":"DR Spigel","year":"2021","unstructured":"Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331:631\u2013641. Ann Oncol. 2021;32:631\u201341. https:\/\/doi.org\/10.1016\/j.annonc.2021.01.071.","journal-title":"Ann Oncol"},{"key":"3654_CR9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jtho.2019.01.008","volume":"14","author":"JL Pujol","year":"2019","unstructured":"Pujol JL, Greillier L, Audigier-Valette C, Moro-Sibilot D, Uwer L, Hureaux J, et al. A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: results from the IFCT-1603 Trial. J Thorac Oncol. 2019;14:903\u201313. https:\/\/doi.org\/10.1016\/j.jtho.2019.01.008.","journal-title":"J Thorac Oncol"},{"key":"3654_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamaoncol.2022.5631","volume":"9","author":"WJ Petty","year":"2023","unstructured":"Petty WJ, Paz-Ares L. Emerging strategies for the treatment of small cell lung cancer: a review. JAMA Oncol. 2023;9:419\u201329. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5631.","journal-title":"JAMA Oncol"},{"key":"3654_CR11","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","volume":"78","author":"YY Syed","year":"2018","unstructured":"Syed YY. Anlotinib: first global approval. Drugs. 2018;78:1057\u201362. https:\/\/doi.org\/10.1007\/s40265-018-0939-x.","journal-title":"Drugs"},{"key":"3654_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41416-021-01356-3","volume":"125","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Wang Q, Li K, Shi J, Liu Y, Wu L, et al. Anlotinib vs. placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled phase 2 study. Br J Cancer. 2021;125:366\u201371. https:\/\/doi.org\/10.1038\/s41416-021-01356-3.","journal-title":"Br J Cancer"},{"key":"3654_CR13","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288\u2013301. https:\/\/doi.org\/10.1056\/NEJMoa1716948.","journal-title":"N Engl J Med"},{"key":"3654_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1200\/jco.2010.29.8851","volume":"29","author":"R Jotte","year":"2011","unstructured":"Jotte R, Conkling P, Reynolds C, Galsky MD, Klein L, Fitzgibbons JF, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol. 2011;29:287\u201393. https:\/\/doi.org\/10.1200\/jco.2010.29.8851.","journal-title":"J Clin Oncol"},{"key":"3654_CR15","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1200\/jco.2006.06.5821","volume":"24","author":"MER O\u2019Brien","year":"2006","unstructured":"O\u2019Brien MER, Ciuleanu T-E, Tsekov H, Shparyk Y, \u010cu\u010devi\u00e1 B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24:5441\u20137. https:\/\/doi.org\/10.1200\/jco.2006.06.5821.","journal-title":"J Clin Oncol"},{"key":"3654_CR16","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1200\/jco.23.02110","volume":"42","author":"DR Spigel","year":"2024","unstructured":"Spigel DR, Dowlati A, Chen Y, Navarro A, Yang JC-H, Stojanovic G, et al. RESILIENT part 2: a randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer. J Clin Oncol. 2024;42:2317\u201326. https:\/\/doi.org\/10.1200\/jco.23.02110.","journal-title":"J Clin Oncol"},{"key":"3654_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","volume":"14","author":"N Ready","year":"2019","unstructured":"Ready N, Farago AF, De Braud F, Atmaca A, Hellmann MD, Schneider JG, et al. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol. 2019;14:237\u201344. https:\/\/doi.org\/10.1016\/j.jtho.2018.10.003.","journal-title":"J Thorac Oncol"},{"key":"3654_CR18","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","volume":"15","author":"HC Chung","year":"2020","unstructured":"Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH Jr, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15:618\u201327. https:\/\/doi.org\/10.1016\/j.jtho.2019.12.109.","journal-title":"J Thorac Oncol"},{"key":"3654_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","volume":"7","author":"D Carvajal-Hausdorf","year":"2019","unstructured":"Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, et al. Expression and clinical significance of PD-L1, B7\u2013H3, B7\u2013H4 and TILs in human small cell lung cancer (SCLC). J Immunother Cancer. 2019;7:65. https:\/\/doi.org\/10.1186\/s40425-019-0540-1.","journal-title":"J Immunother Cancer"},{"key":"3654_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.lungcan.2017.07.030","volume":"112","author":"Y He","year":"2017","unstructured":"He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, et al. MHC class II expression in lung cancer. Lung Cancer. 2017;112:75\u201380. https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.030.","journal-title":"Lung Cancer"},{"key":"3654_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/s0002-9440(10)64181-8","volume":"161","author":"T Yazawa","year":"2002","unstructured":"Yazawa T, Ito T, Kamma H, Suzuki T, Okudela K, Hayashi H, et al. Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma. Am J Pathol. 2002;161:291\u2013300. https:\/\/doi.org\/10.1016\/s0002-9440(10)64181-8.","journal-title":"Am J Pathol"},{"key":"3654_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3233\/cbm-150473","volume":"15","author":"T Tian","year":"2015","unstructured":"Tian T, Gu X, Zhang B, Liu Y, Yuan C, Shao L, et al. Increased circulating CD14(+)HLA-DR-\/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer. Cancer Biomark. 2015;15:425\u201332. https:\/\/doi.org\/10.3233\/cbm-150473.","journal-title":"Cancer Biomark"},{"key":"3654_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247494","volume":"16","author":"S Ghozy","year":"2021","unstructured":"Ghozy S, Yu G, Cai Q, Xu X, Shen Y, Xu K. Anlotinib-containing regimen for advanced small-cell lung cancer: a protocol of meta-analysis. PLoS ONE. 2021;16: e0247494. https:\/\/doi.org\/10.1371\/journal.pone.0247494.","journal-title":"PLoS ONE"},{"key":"3654_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102606","volume":"120","author":"Y Chen","year":"2023","unstructured":"Chen Y, Li H, Fan Y. Shaping the tumor immune microenvironment of SCLC: mechanisms, and opportunities for immunotherapy. Cancer Treat Rev. 2023;120: 102606. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102606.","journal-title":"Cancer Treat Rev"},{"key":"3654_CR25","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA. 2012;109:17561\u20136. https:\/\/doi.org\/10.1073\/pnas.1215397109.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3654_CR26","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s00262-020-02641-5","volume":"69","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li L, Jiang Z, Wang B, Pan Z. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer. Cancer Immunol Immunother. 2020;69:2523\u201332. https:\/\/doi.org\/10.1007\/s00262-020-02641-5.","journal-title":"Cancer Immunol Immunother"},{"key":"3654_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jtho.2020.10.002","volume":"16","author":"Y Fan","year":"2021","unstructured":"Fan Y, Zhao J, Wang Q, Huang D, Li X, Chen J, et al. Camrelizumab plus apatinib in extensive-stage SCLC (PASSION): a multicenter, two-stage, phase 2 Trial. J Thorac Oncol. 2021;16:299\u2013309. https:\/\/doi.org\/10.1016\/j.jtho.2020.10.002.","journal-title":"J Thorac Oncol"},{"key":"3654_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00432-021-03858-2","volume":"148","author":"Q Chen","year":"2021","unstructured":"Chen Q, Li Y, Zhang W, Wang C, Yang S, Guo Q. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study. J Cancer Res Clin Oncol. 2021;148:401\u20138. https:\/\/doi.org\/10.1007\/s00432-021-03858-2.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3654_CR29","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.1002\/cam4.5360","volume":"12","author":"L Yu","year":"2022","unstructured":"Yu L, Xu J, Qiao R, Han B, Zhong H, Zhong R. Efficacy and safety of anlotinib combined with PD-1\/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer. Cancer Med. 2022;12:5372\u201383. https:\/\/doi.org\/10.1002\/cam4.5360.","journal-title":"Cancer Med"},{"key":"3654_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102543","volume":"70","author":"S Ma","year":"2024","unstructured":"Ma S, He Z, Liu Y, Wang L, Yang S, Wu Y, et al. Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial. EClinicalMedicine. 2024;70: 102543. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102543.","journal-title":"EClinicalMedicine"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03654-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03654-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03654-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T05:43:56Z","timestamp":1742190236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03654-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["3654"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03654-7","relation":{},"ISSN":["1699-3055"],"issn-type":[{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"6 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and the protocol was approved by the ethics committee of each institution involved in the project. Under the condition of retrospective archival tissue collection and patient data anonymization, our study was exempt from the acquisition of informed consent from patients by the institutional review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}